Tecentriq (atezolizumab)

Tecentriq is manufactured by Roche in Switzerland and shipped by courier from our pharmacy in India.

Information about Tecentriq (Atezolizumab)

Tecentriq is the brand name for atezolizumab, a monoclonal antibody that belongs to a class of cancer immunotherapies known as immune checkpoint inhibitors. Atezolizumab works by targeting the PD-L1 (programmed death-ligand 1) protein found on cancer cells and immune cells. By blocking PD-L1, Tecentriq helps to activate the body's immune system to recognize and destroy cancer cells.

Product Highlights

• Tecentriq is used to treat patients with advanced or metastatic NSCLC, particularly those whose tumors express PD-L1 and who have not responded to other chemotherapy treatments.
• Tecentriq is indicated for patients with locally advanced or metastatic urothelial carcinoma (bladder cancer) who have previously received platinum-containing chemotherapy.
• In combination with chemotherapy, Tecentriq is used to treat metastatic triple-negative breast cancer that expresses PD-L1.
• Tecentriq is used in combination with another medication, bevacizumab, to treat unresectable or metastatic hepatocellular carcinoma (liver cancer) in patients who have not previously received systemic therapy.
• Tecentriq is used in combination with chemotherapy for the treatment of extensive-stage small cell lung cancer.

Key Ingredient

• Atezolizumab

Key Benefits

• By blocking PD-L1, Tecentriq helps reactivate the immune system to recognize and target cancer cells more effectively.
• Immune checkpoint inhibitors like Tecentriq have shown the potential to provide durable responses in certain cancers, leading to long-term survival in some patients.
• Immunotherapy, including Tecentriq, typically has a different side effect profile than chemotherapy, often leading to less damage to healthy tissues.
• Tecentriq is approved for several cancer types, making it a versatile option for treating advanced or metastatic cancers.

Direction of Use

• Tecentriq is administered by intravenous infusion in a healthcare setting, usually every 2 to 3 weeks, depending on the specific cancer being treated and the treatment regimen.
• The dose of Tecentriq depends on the type of cancer, body weight, and response to treatment. The healthcare provider will determine the appropriate dosing schedule.
• The duration of treatment with Tecentriq is individualized, and therapy may continue as long as the patient is responding to treatment and is tolerating it well.

Safety Concerns

• Since Tecentriq works by activating the immune system, it can cause the immune system to attack healthy tissues, leading to immune-related adverse events. These can affect organs such as the lungs, liver, colon, thyroid, kidneys, and others.
• Some patients may experience reactions during or after the infusion, such as fever, chills, rash, or difficulty breathing.
• As Tecentriq enhances immune responses, it may increase the risk of infections, including serious infections like pneumonia or sepsis.
• Tecentriq may cause liver damage, so liver function should be monitored regularly during treatment.
• Inflammation of the lungs (pneumonitis) can occur, which can be severe and may require treatment discontinuation.
• Immune-related side effects may include thyroid dysfunction, adrenal insufficiency, and other endocrine problems.
• Patients with certain pre-existing conditions, such as autoimmune diseases, may be at higher risk for severe side effects.

Avoid Tecentriq (Atezolizumab) If

• If you have a known allergy to atezolizumab or any of its ingredients, you should avoid using Tecentriq.
• Patients with active autoimmune diseases may be at increased risk of immune-related side effects, and Tecentriq should be used cautiously or avoided.
• If you have an active infection, Tecentriq may be contraindicated, as it could worsen infection risks.
• Tecentriq should be avoided in patients with severe liver disease, as it may worsen liver function.
• Tecentriq is classified as a Category D drug in pregnancy, meaning it may harm a fetus. It should not be used during pregnancy, and effective contraception is advised during treatment.
• Tecentriq is not recommended during breastfeeding, as it is not known whether it is excreted in breast milk.

This product requires special packaging to maintain its integrity during the shipping process. DO NOT USE THIS MEDICATION if the attached temperature indicator shows that the medication was exposed to temperatures below 2 degrees or above 8 degrees Celsius, and contact the pharmacy immediately.